Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, announced that a comprehensive summary of clinical trials evaluating HyBryte(TM) (synthetic hypericin) for cutaneous T-cell lymphoma has been published in the peer-reviewed journal Expert Opinion on Investigational Drugs. The publication highlights the therapy's safety profile, non-mutagenic mechanism and demonstrated efficacy across studies, while supporting its potential as a first-line treatment option as the company advances its ongoing FLASH2 Phase 3 trial with interim analysis expected in the second quarter of 2026.
The importance of this peer-reviewed publication lies in its validation of HyBryte's clinical data through independent scientific scrutiny, which strengthens the therapy's credibility as it progresses through regulatory pathways. For patients suffering from cutaneous T-cell lymphoma, a rare cancer affecting the skin, this represents progress toward a potentially safer treatment option with a non-mutagenic mechanism that could reduce long-term health risks associated with current therapies. The publication's timing coincides with the company's advancement of its FLASH2 Phase 3 trial, suggesting growing momentum toward potential regulatory approval and commercialization.
Soligenix's Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma. With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin into psoriasis, first-in-class innate defense regulator technology for inflammatory diseases, and treatments for Behçet's Disease.
The company's Public Health Solutions business segment includes development programs for vaccine candidates targeting ricin toxin, filoviruses such as Marburg and Ebola, and CiVax(TM) for COVID-19 prevention. This business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency and the Biomedical Advanced Research and Development Authority. The latest news and updates relating to SNGX are available in the company's newsroom at https://ibn.fm/SNGX.
For the biopharmaceutical industry, Soligenix's progress with HyBryte demonstrates the viability of developing treatments for rare diseases through focused research and clinical development. The peer-reviewed publication provides independent validation that could influence regulatory decisions and potentially accelerate the therapy's path to market. As the company advances its Phase 3 trial with interim analysis expected in 2026, investors and industry observers will monitor whether the published data translates into successful clinical outcomes and eventual regulatory approval.
